Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash
134 tokens/sec
GPT-4o
10 tokens/sec
Gemini 2.5 Pro Pro
47 tokens/sec
o3 Pro
4 tokens/sec
GPT-4.1 Pro
38 tokens/sec
DeepSeek R1 via Azure Pro
28 tokens/sec
2000 character limit reached

Robust Hybrid Learning for Estimating Personalized Dynamic Treatment Regimens (1611.02314v1)

Published 7 Nov 2016 in stat.ME

Abstract: Dynamic treatment regimens (DTRs) are sequential decision rules tailored at each stage by potentially time-varying patient features and intermediate outcomes observed in previous stages. The complexity, patient heterogeneity and chronicity of many diseases and disorders call for learning optimal DTRs which best dynamically tailor treatment to each individual's response over time. Proliferation of personalized data (e.g., genetic and imaging data) provides opportunities for deep tailoring as well as new challenges for statistical methodology. In this work, we propose a robust hybrid approach referred as Augmented Multistage Outcome-Weighted Learning (AMOL) to integrate outcome-weighted learning and Q-learning to identify optimal DTRs from the Sequential Multiple Assignment Randomization Trials (SMARTs). We generalize outcome weighted learning (O-learning; Zhao et al.~2012) to allow for negative outcomes; we propose methods to reduce variability of weights in O-learning to achieve numeric stability and higher efficiency; finally, for multiple-stage SMART studies, we introduce doubly robust augmentation to machine learning based O-learning to improve efficiency by drawing information from regression model-based Q-learning at each stage. The proposed AMOL remains valid even if the Q-learning model is misspecified. We establish the theoretical properties of AMOL, including the consistency of the estimated rules and the rates of convergence to the optimal value function. The comparative advantage of AMOL over existing methods is demonstrated in extensive simulation studies and applications to two SMART data sets: a two-stage trial for attention deficit and hyperactive disorder (ADHD) and the STAR*D trial for major depressive disorder (MDD).

Citations (32)

Summary

We haven't generated a summary for this paper yet.